Готові списки джерел за темами / Infections à Acinetobacter – Chimiothérapie

Добірка наукової літератури з теми "Infections à Acinetobacter – Chimiothérapie"

Автор: Grafiati
Опубліковано: 15 червня 2024

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Infections à Acinetobacter – Chimiothérapie".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Зміст

  1. Статті в журналах
  2. Дисертації
  3. Книги
  4. Частини книг
  5. Тези доповідей конференцій
  6. Звіти організацій

Статті в журналах з теми "Infections à Acinetobacter – Chimiothérapie":

1

Wilson, Brigid M., Federico Perez, Qing Pan, Yunyun Jiang, Scott R. Evans, and Robert A. Bonomo. "Acinetobacter Infections." Clinical Infectious Diseases 71, no. 5 (November 17, 2019): 1357–58. http://dx.doi.org/10.1093/cid/ciz1099.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Snoeck, R., and E. De Clercq. "La chimiothérapie des infections a cytomégalovirus." Médecine et Maladies Infectieuses 18 (March 1988): 79–84. http://dx.doi.org/10.1016/s0399-077x(88)80102-1.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Özgür, Özlem, and Necmi Aksaray. "Acinetobacter Infections and Treatment." Journal of Pediatric Infection 8, no. 1 (March 17, 2014): 28–32. http://dx.doi.org/10.5152/ced.2013.38.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Joly-Guillou, M. L. "Acinetobacter et infections nosocomiales." Revue Française des Laboratoires 2002, no. 345 (September 2002): 14. http://dx.doi.org/10.1016/s0338-9898(02)80247-5.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Falagas, M. E., E. A. Karveli, I. Kelesidis, and T. Kelesidis. "Community-acquired Acinetobacter infections." European Journal of Clinical Microbiology & Infectious Diseases 26, no. 12 (August 16, 2007): 857–68. http://dx.doi.org/10.1007/s10096-007-0365-6.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Garnacho-Montero, José, and Jean-François Timsit. "Managing Acinetobacter baumannii infections." Current Opinion in Infectious Diseases 32, no. 1 (February 2019): 69–76. http://dx.doi.org/10.1097/qco.0000000000000518.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Bergogne-Bérézin, E. "Treatment of Acinetobacter infections." Expert Opinion on Investigational Drugs 6, no. 2 (February 1997): 119–27. http://dx.doi.org/10.1517/13543784.6.2.119.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Miah, Md Ruhul Amin. "Acinetobacter baumannii Hospital Acquired Infections." Bangladesh Journal of Medical Microbiology 13, no. 1 (January 10, 2019): 1–3. http://dx.doi.org/10.3329/bjmm.v13i1.51778.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Fleming, Irma D., Monika A. Krezalek, Natalia Belogortseva, Alexander Zaborin, Jennifer Defazio, Laxmipradha Chandrasekar, Luis A. Actis, Olga Zaborina, and John C. Alverdy. "Modeling Acinetobacter baumannii wound infections." Journal of Trauma and Acute Care Surgery 82, no. 3 (March 2017): 557–65. http://dx.doi.org/10.1097/ta.0000000000001338.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Levin, Anna S. "Treatment of Acinetobacter spp. infections." Expert Opinion on Pharmacotherapy 4, no. 8 (August 2003): 1289–96. http://dx.doi.org/10.1517/14656566.4.8.1289.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел
Також вас можуть зацікавити розширені добірки на тему "Infections à Acinetobacter – Chimiothérapie" для конкретних типів джерел:
Статті в журналах Дисертації Книги

Дисертації з теми "Infections à Acinetobacter – Chimiothérapie":

1

Antraygues, Kévin. "Conception, synthèse et évaluation biologique de nouveaux ansamacrolides dans le traitement d'infections bactériennes." Electronic Thesis or Diss., Université de Lille (2022-....), 2022. http://www.theses.fr/2022ULILS027.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
L'antibiorésistance est un problème de santé publique majeur à l'heure actuelle et ceci sera d'autant plus vrai dans les prochaines décennies. Parmi les bactéries impliquées dans ce phénomène alarmant, Acinetobacter baumannii et Mycobacterium abscessus ont développé toutes deux des résistantes à de nombreux antibiotiques actuellement disponibles sur le marché. La recherche et le développement de nouveaux antibiotiques est donc nécessaire afin de lutter contre ces pathogènes.La rifabutine, un macrocycle hémisynthétique de la classe des rifamycines, a récemment montré des activités intéressantes in vitro contre A. baumannii et M. abscessus, ce qui s'est traduit ensuite par une efficacité in vivo de la molécule. La rifabutine semble donc prometteuse dans la lutte contre ces bactéries, cependant l'emploi de cet antibiotique est à ce jour limité. Afin de traiter une infection causée par A. baumannii, la rifabutine doit être injectée par voie intraveineuse, ce qui n'est pas chose simple au vue de la faible solubilité aqueuse de la molécule. Concernant la lutte contre M. abscessus, la rifabutine, bien qu'efficace in vivo, présente une activité limitée contre cette mycobactérie, ce qui peut conduire à un échappement thérapeutique.Les travaux présentés dans ce manuscrit de thèse cherchent donc à pallier les limitations de la rifabutine mentionnées ci-dessus.Dans une première partie, des prodrogues hydrosolubles de la rifabutine ont été synthétisées dans le but de permettre une administration par voie intraveineuse et ainsi de lutter efficacement contre des infections à A. baumannii en clinique. Afin de conduire à la libération de rifabutine après clivage enzymatique dans le plasma, une stratégie de cyclisation intramoléculaire a été employée. Après l'évaluation des composés lors de tests de stabilité plasmatique, des études de relations structure-stabilité ont été réalisées, menant à l'identification de trois prodrogues prometteuses. Des études in vitro supplémentaires ont ensuite été conduites telles que la mesure de la solubilité aqueuse et de l'inhibition de la croissance bactérienne, puis une étude in vivo de pharmacocinétique a finalement été réalisée afin d'identifier un candidat pour le développement.Dans une seconde partie, des analogues de la rifabutine modifiée en position C25 ont été synthétisés afin d'identifier des composés plus puissants. En se basant sur une stratégie de chimie en parallèle, un grand nombre de dérivés a pu rapidement être obtenu, puis ceux-ci ont été évalués contre M. abscessus dans le but de mener des études de relations structure-activité
Antimicrobial resistance is a major public health issue nowadays and this will be even more true in the coming decades. Among the bacteria involved in this alarming phenomenon, Acinetobacter baumannii and Mycobacterium abscessus are both resistant to many antibiotics currently available on the market. Research and development of new antibiotics is therefore necessary to fight these pathogens.Rifabutin, a semi-synthetic macrocyle of the rifamycin class, has recently shown interesting in vitro activities against A. baumannii and M. abscessus, which then translated into in vivo efficacy. Rifabutin therefore seems to be promising to the fight against these bacteria, but the use of this antibiotic is currently limited. In order to treat an infection caused by A. baumannii, rifabutin requires to be injected by intravenous route, which is not so easy because of the low water solubility of the molecule. Concerning the treatment of M. abscessus infections, rifabutin, although effective in vivo, has moderate activity against this mycobacterium, which could lead to therapeutic escape.Therefore, the work presented in this thesis manuscript seeks to address the limitations of rifabutin mentioned above.In a first part, water-soluble prodrugs of rifabutin have been synthesized in order to allow an intravenous injection and thus fight effectively against A. baumannii infections. To achieve the release of rifabutin after enzymatic cleavage in plasma, an intramolecular cyclization strategy was employed. After evaluation of the compounds in plasma stability assays, structure-stability relationship studies were performed, leading to the identification of three promising prodrugs. Additional in vitro studies were then conducted such as the measurement of aqueous solubility and bacterial growth inhibition, and finally an in vivo pharmacokinetic study was performed to be able to select for a preclinical candidate.In a second part, analogues of rifabutin modified at the C25 position were synthesized to identify more potent compounds. Based on a parallel chemistry strategy, a large number of derivatives were rapidly obtained and then evaluated against M. abscessus in order to conduct structure-activity relationship studies
2

Henein, Alexandra Elisabeth. "The potential of bacteriophage therapy in Acinetobacter spp. infections." Thesis, University of Brighton, 2009. https://research.brighton.ac.uk/en/studentTheses/9726f331-e5dc-4b67-a282-44cac1fe978f.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Bacteria resistant to multiple antibiotics pose a number of therapeutic problems. This situation is likely to worsen in the future, as the development of new classes of antibiotics has declined sharply in recent years. Acinetobacter species are an example of antibiotic-resistant bacterial pathogens with increasing clinical significance, particularly with respect to infections in high-risk patients such as those with severe burns. The treatment options for these patients are severely limited, and they often can only be treated with highly toxic antibiotics such as colistin. It is therefore evident that there is a need to investigate alternative approaches to therapy in these cases. This thesis represents some preliminary investigations into the use of bacteriophages for the treatment of Acinetobacter infections of severe burns patients. Bacteriophages are viruses that have bacteria as their host. They cannot attack human cells and indeed they are highly specific for given species of bacteria. The aim of this thesis was to investigate the potential use of bacteriophages in these infections and their possible toxic effects on mammalian (including human skin) cells. Since bacteriophages lytic against Acinetobacter species were not available through conventional culture collections it was necessary to identify other sources. Clinical isolates of Acinetobacter species were obtained from Sussex hospitals and characterised. Several unsuccessful attempts were made to isolate corresponding bacteriophages from the environment and ultimately 10 isolates of Acinetobacter spp. and their corresponding phage were obtained from Laval University, Canada. These bacterial strains were identified and host matched to each phage using a refined screening technique and purified phage preparations were produced for those potentially therapeutic phages. The results of this study formed the basis for the selection of a small number of phage to take forward for cytotoxicity studies. Very little scientific evidence has been published on the cytotoxic potential of bacteriophage or their bacterial lysis products, although phages have been routinely used for therapeutic purposes over many years. The establishment of phages as a mainstream treatment choice for bacterial infections in the West will require stringent testing and proof that phage preparations are not harmful. Human dermal fibroblast (HDF) and keratinocytes (HDK) were isolated from human biopsies. A 3T3 mouse fibroblast cell line, HDF and HDK with 3T3 feeder layers were exposed to dilutions of purified phage. The cytotoxic impact and effect on cell proliferation was measured using a range of assays. No statistically significant difference could be detected between controls and phage with the Trypan blue method (3T3 cells). Hoechst propidium iodide stain experiments remained inconclusive (3T3 cells). Lactate dehydrogenase (LDH) and MTS tetrazolium compound reduction (MTS) results showed no evidence of statistically significant cytotoxic effect of phage on 3T3 cells, HDF or HDK. Some data suggested phage may have some beneficial effect on cell survival of HDK and proliferation of HDF and 3T3 cells compared to controls. Endotoxin levels present in phage lysates and purified phage preparations were compared to those found in bacterial suspensions subjected to lysis by other methods including autoclaving, bead beating, sonication and high concentrations of antibiotics. There was no evidence to suggest that bacteria lysed by phage liberated significantly more endotoxins than the other methods of cell disruption. A variety of endotoxin preparations and phage lysates were incubated with HDF and cytotoxicity together with cell proliferation were measured using LDH and MTS assays. Changes in interleukin levels of the same samples were monitored, measuring IL-1β, IL-6, IL-8 and TNF-α levels. IL-1β or TNF-α could not be detected in any samples. Highly concentrated phage gave rise to significantly higher IL-6 outputs than any other samples. Ten-fold dilutions of the same phage preparation were not statistically different to any other samples, including controls. This suggested components introduced during the phage purification process, rather than the phage itself may have contributed to higher IL-6 readings. Purified and crude phage lysate gave rise to significantly higher IL-8 outputs than all other samples. Colony formation assays utilising a V79 hamster cell line were used to indicate the cytotoxicity of purified phage in different diluents and provided comparison with endotoxin containing preparations used in other experiments. There was no statistically significant difference in terms of colony numbers or colony size (where measured) between phage samples and controls. This thesis has therefore demonstrated that because of the lack of cytotoxic effect of phage on mammalian cells in culture, there is potential for therapeutic applications of bacteriophage.
3

Diallo, Bruno Salla. "Études des acinetobacter : à propos de 98 souches isolées en milieu hospitalier." Bordeaux 2, 1990. http://www.theses.fr/1990BOR23091.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Gagné, Stéphanie. "Étude des mécanismes de virulence du pathogène nosocomial Acinetobacter baumannii." Thesis, Lyon, 2018. http://www.theses.fr/2018LYSE1045/document.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Acinetobacter baumannii est un pathogène nosocomial qui induit principalement des infections du système respiratoire ou urinaire, et des septicémies chez les patients immunodéprimés. L'émergence de souches multi résistantes aux antibiotiques et l'augmentation de nombreuses d'infections par A. baumannii fait de ce pathogène un enjeu majeur de santé publique. De plus aujourd'hui émerge des souches hypervirulentes. Nous nous sommes intéressés à différentes souches afin de caractériser le phénotype hypervirulent de ces souches. L'étude du système de sécrétion de type VI montre la complexité des mécanismes de virulence d'A. baumannii et sa régulation dépendante des souches. Dans un second temps l'étude des souches cliniques hypervirulentes et nous avons mis en évidence deux nouveaux potentiels mécanismes de virulence : une phase de réplication intracellulaire et une limitation de la réponse immunitaire. Ces mécanismes peuvent expliquer la virulence accrue de ces souches chez l'homme. L'étude nous montre également qu'A. baumannii est un pathogène complexe et qu'on son étude à l'heure actuelle nécessité l'emploi de souche représentative des souches infectant les patients
A. baumannii is an hospital acquired pathogen which causes mainly ventilator associated infection, urinary tract infection and bacteraemia. Last years Multi Drug Resistant strains increase and nosocomial infection cause by A. baumannii also which led him as a serious health care problem. We compare different strains in propose to find phenotype that can explain hypervirulent strain emergence. We studied type six secretion and showed that the complexity of A. baumannii virulence mechanism. Indeed type six secretion system regulation is strain dependant. Secondary we study hypervirulent strain and showed that intracellular stage exists and there is intracellular replication. Also hypervirulent strain induces less immune response. Those two mechanisms can explain A. baumannii hypervirulent phenotype
5

Fabre, David. "Approche pharmacocinétique de l'antibiothérapie dans les infections pulmonaires." Montpellier 1, 1995. http://www.theses.fr/1995MON13504.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Hauret, Sylvie. "Epidémiologie moléculaire d'infections nosocomiales à Acinetobacter Baumannii dans un service de réanimation." Bordeaux 2, 1996. http://www.theses.fr/1996BOR2P039.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Webster, Carol Ann. "The use of molecular typing systems for studying the epidemiology of Acinetobacter infections." Thesis, University of Nottingham, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.388315.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Chou, So-ha, and 周素霞. "Molecular epidemiology of carbapenem-resistant acinetobacter baumanniiin patients and their surrounding environment." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2012. http://hub.hku.hk/bib/B48333669.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Background There has been an increasing awareness of the role of the hospital environment as a reservoir of Acinetobacter baumannii. A. baumannii is an important nosocomial pathogen and is difficult to control due to the increasing cases of resistance to carbapenem. Objectives The objectives of this study areto examine carbapenem-resistant Acinetobacter baumannii (CRAB) positive patients according to their environmental sample to determine how frequently the environment surrounding the patient becomes contaminated and which environmental surfaces are most commonly contaminated. Methodology During June 2011 to December 2011, data regarding 30 hospitalized patients with at least one positive CRAB clinical sample were collected from hospital X in Kowloon of Hong Kong. For 30 case patients, one patient in the ICU ward had been isolated in a single room and the other 29 patients stayed in a multi-room. Fifteen surfaces in the patient cubicle and nine surfaces in health care worker stations were evaluated for the presence of CRAB. 29 control environmental samples were obtained from the surroundings of patients without CRAB in the same cubicle and one control environmental sample was obtained from the surroundings of patients without CRAB in the other room of ICU. Pulsed-field gel electrophoresis was performed on all environmental isolates and clinical samples. Results Of the 30casepatients, 26 patients (86.7%) were found to have CRAB contamination in their surrounding environment and 6negative control patients (20%) were found to have CRAB in their environmental samples. The percentage of positive CRAB cultures in the case environment, control and health care worker stations was 28.9% (117/405), 3.4% (14/406) and 1.9% (5/265)respectively. In the surrounding case patient area, pillows (60% 18/30) and bed sheets on which the patients sleep on (60% 18/30), bed sheets covering the patients (50% 15/30) and bedside table tops (40% 12/30) were the most commonly contaminated. For 26casepatientswere found to have CRAB contamination in their surrounding environment, 23 (88.5%) of these patients were found to have the clone of isolates in the case environment related to the patients. Conclusion For patients with CRAB, the surrounding environment is frequently contaminated. Surfaces often touched by the patients are commonly contaminated. CRAB was also found on surfaces that were not closely related to the patient which are frequently touched by healthcare workers during patient care.
published_or_final_version
Microbiology
Master
Master of Medical Sciences
9

Brandely, Marie-Laure. "Nouvelles prises en charge des principales infections fongiques hospitalières : évaluation pharmaco-économique." Paris 5, 1999. http://www.theses.fr/1999PA05P183.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Adegoke, Anthony Ayodeji. "Commensal bacteria belonging to the Staphylococcus Acinetobacter and Stenotrophomonas genera as reservoirs of antibiotic resistance determinants in the environment of Nkonkobe Municipality, Eastern Cape Province , South Africa." Thesis, University of Fort Hare, 2012. http://hdl.handle.net/10353/6539.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
A study to assess the potentials of some commensal bacteria that belong to Staphylococcus, Acinetobacter and Stenotrophomonas genera as reservoirs of antibiotic resistance determinants in the environment of Nkonkobe Municipality of the Eastern Cape Province, South Africa, was carried out using standard microbiological and molecular techniques. A total of 120 Staphylococcus isolates which consisted of Staphylococcus haemolyticus (30%), Staphylococcus aureus (23.3%) from pig; Staphylococcus capitis (15%) from goat; Staphylococcus heamolyticus (5%) and Staphylococcus xylosus (15%) from cattle and other Staphylococci (11%) from dead chicken and pigs were isolated. About 23.3% of these isolates were coagulase positive and 76.7% were coagulase negative. This difference in prevalence along coagulase production divide was statistically significant (p < 0.05). Eighty-six Acinetobacter species (Acinetobacter baumannii/calcoaceticus and Acinetobacter haemolyticus) were also isolated from Alice and Fort Beaufort towns samples, while 125 Stenotrophomonas maltophilia isolates were from grass root rhizosphere (96%) and soil butternut root rhizosphere (4%). Between 75-100% of the Staphylococccus species were resistant to Penicillin G, tetracycline, sulphamethaxole and nalidixic acid; about 38 % were methicillin resistant, consisting of 12.6% methicillin resistant Staphylococcus aureus (MRSA) from pig and a total of 12% vancomycin resistant were observed. Also, 12% of the isolates were erythromycin resistant while 40.2 % were resistant to the third generation cephalosporin, ceftazidime. The antibiotic resistance genes vanA, VanB, eryA, eryB, eryC were not detected in all the phenotypically resistant Staphylococccus species, but mec A gene and mph genes were detected. In the Acinetobacter species, a wide range of 30-100% resistance to penicillin G, ceftriazone, nitrofurantoin, erythromycin, and augmentin was observed. Polymerase chain reaction (PCR) revealed the presence of Tet(B) and Tet(39) genes in these species, while Tet (A), Tet(M) and Tet(H) were absent. Also, 9.3% of the Acinetobacter species showed phenotypic production of extended spectrum beta lactamases (ESBLs) while 3.5% were positive for the presence of blaCTX-M-1 genes. The Stenotrophomonas maltophilia isolates showed varying resistance to meropenem (8.9%), cefuroxime (95.6 %), ampicillin-sulbactam (53.9%), ceftazidime (10.7%), cefepime (29.3 %), minocycline (2.2%), kanamycin (56.9%), ofloxacin (2.9%), levofloxacin (1.3%), moxifloxacin (2.8%), ciprofloxacin (24.3%), gatifloxacin (1.3%), polymyxin B (2.9 %), cotrimoxazole (26.1%), trimethoprim (98.6%), aztreonam(58%) and Polymyxin B (2.9 %). The isolates exhibited significant susceptibility to the fluoroquinolones (74.3-94.7 %), polymycin (97.1%) and meropenem (88.1%). Only sul3 genes were the only sulphonamide resistance gene detected among the trimethoprim-sulphamethoxazole resistant isolates. The observed multiple antibiotic resistance indeces (MARI) of >2 for Staphylococcus species, Acinetobacter species and Stenotrophomonas maltophilia suggest that they have arisen from high-risk sources where antibiotics are in constant arbitrary use resulting in high selective pressure. The presence of tetracycline resistance genes in Acinetobacter species justifies the observed phenotypic resistance to oxytetracycline and intermediate resistance to minocycline. High phenotypic resistance and the presence of some resistance genes in Staphylococcus species is a possible threat to public health and suggests animals to be important reservoirs of antibiotic resistance determinants in the environment. Indiscriminate use of antibiotics induces this kind of antibiotic resistance and should be discouraged. Personal hygiene is encouraged as it reduces the load of Acinetobacter species contacted from the environment that may be difficult to control. Commensal Stenotrophomonas maltophilia are as important as their clinical counterparts due to their roles in opportunistic infection, antibiotic resistance and their associated genes, especially sul gene. Personal hygiene is hereby advocated especially when in contact with soil, plants and plants’ rhizospheric soil
Більше джерел

Книги з теми "Infections à Acinetobacter – Chimiothérapie":

1

E, Bergogne-Bérézin, Joly-Guillou M. L, and Towner K. J, eds. Acinetobacter: Microbiology, epidemiology, infections, management. Boca Raton: CRC Press, 1996.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

E, Bergogne-Bérézin, Friedman Herman 1931-2007, and Bendinelli Mauro, eds. Acinetobacter biology and pathogenesis. New York: Springer, 2008.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

E, Bergogne-Bérézin, Friedman Herman 1931-2007, and Bendinelli Mauro, eds. Acinetobacter biology and pathogenesis. New York: Springer, 2008.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Ulrike, Gerischer, ed. Acinetobacter molecular biology. [Wymondham?]: Caister Academic Press, 2008.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Jacques, Thèze, and Debré Patrice, eds. Le sida à l'ère des multithérapies. Paris: Elsevier, 2000.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Dariosecq, Jean-Michel. Infection VIH: Mémento thérapeutique 2003. 6th ed. Rueil-Malmaison: Doin, 2003.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Taylor, Yolanda. Battling HIV/AIDS: A decision maker's guide to the procurement of medicines and related supplies. Washington, DC: World Bank, 2004.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

P, Sawan Samuel, and Manivannan Gurusamy 1960-, eds. Antimicrobial/anti-infective materials: Principles, applications and devices. Lancaster, Pa: Technomic Pub. Co., 2000.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Friedman, Herman, Mauro Bendinelli, and Eugénie Bergogne-Bérézin. Acinetobacter: Biology and Pathogenesis. Springer, 2010.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Bergogne-Berezin, E., Marie-Laure Joly-Guillou, and Kevin J. Towner. Acinetobacter: Microbiology, Epidemiology, Infections, Management. Taylor & Francis Group, 2020.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Частини книг з теми "Infections à Acinetobacter – Chimiothérapie":

1

Champion, Howard R., Nova L. Panebianco, Jan J. De Waele, Lewis J. Kaplan, Manu L. N. G. Malbrain, Annie L. Slaughter, Walter L. Biffl, et al. "Acinetobacter Infections." In Encyclopedia of Intensive Care Medicine, 41–47. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-00418-6_3.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Dijkshoorn, Lenie. "Acinetobacter baumannii." In Molecular Typing in Bacterial Infections, 433–56. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-62703-185-1_25.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Nurjadi, Dennis, and Sébastien Boutin. "Acinetobacter baumannii." In Molecular Typing in Bacterial Infections, Volume II, 113–29. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-83217-9_6.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Joly-Guillou, M. L. "Nosocomial and Community-acquired Acinetobacter Infections." In Acinetobacter Biology and Pathogenesis, 155–65. New York, NY: Springer US, 2008. http://dx.doi.org/10.1007/978-0-387-77944-7_9.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Baneman, Emily, and Meenakshi M. Rana. "Management of Acinetobacter Infections in the Immunosuppressed Host." In Emerging Transplant Infections, 1–19. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-01751-4_21-1.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Baneman, Emily, and Meenakshi M. Rana. "Management of Acinetobacter Infections in the Immunosuppressed Host." In Emerging Transplant Infections, 371–89. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-25869-6_21.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Rajkumari, Jobina, and Busi Siddhardha. "Acinetobacter baumannii: Infections and Drug Resistance." In Model Organisms for Microbial Pathogenesis, Biofilm Formation and Antimicrobial Drug Discovery, 257–71. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-1695-5_14.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Rubinstein, E., and I. Levi. "Acinetobacter Infections in Intensive Care Units." In Yearbook of Intensive Care and Emergency Medicine, 542–51. Berlin, Heidelberg: Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-642-80053-5_44.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Joly-Guillou, M. L., E. Bergogne-Bérézin, and J. F. Vieu. "Epidemiology of Acinetobacter Strains Isolated from Nosocomial Infections in France." In The Biology of Acinetobacter, 63–68. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4899-3553-3_5.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Vergidis, Paschalis, and Matthew E. Falagas. "Control of Multi-Drug Resistant Acinetobacter Infections." In Antibiotic Policies, 117–25. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-1734-8_10.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Infections à Acinetobacter – Chimiothérapie":

1

K. Alkhudhairy, Miaad, та Elhassan Benyagoub. "Frequency of Genes Mediated β-lactams Resistance in Acinetobacter Baumannii Isolates from Iraq". У X INTERNATIONAL CONGRESS OF PURE AND APPLIED TECHNOLOGICAL SCIENCES. Rimar Academy, 2023. http://dx.doi.org/10.47832/minarcongress10-2.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Background: Acinetobacter baumannii is a nosocomial virulent microorganism that can cause acute and chronic infections in burn patients. The aim of the study: Diagnosis of genes mediated β-lactams resistance among test isolates. Materials and Methods: 649 swabs collected from inpatients with burn-wound infections at a burn center in Al-Najaf Province/ Iraq, from August 2022 to February 2023. Results: 68/ 649 (10.5%) isolates of Acinetobacter baumannii were identified according to microscopically, cultural, and biochemical features. 22 (32.4%) isolates were found able to produce extended-spectrum β-lactamases by using the double disks synergy method, and these producers tested by polymerase chain reactions technique for molecular determination β-lactams resistance encoding genes. This technique determined that the frequency of a single blaTEM gene and a single blaCTXM gene was 3/ 22 (13.6%) for each one among the test isolates and that 9/ 22 (41%) isolates possessed linked genes: the blaCTXM and blaTEM genes, whereas the blaSHV gene was not identified in any test isolate. Conclusions: The co-associated (blaTEM and blaCTXM) genes were revealed to be prevalent among the test isolates
2

Al-Ghanimi, Ali Abdul Kadhim, and Amaal Sahib Al-Zughaibi. "Molecular Identification of Acinetobacter baumannii and Staphylococcus aureus isolated from wound infections in Karbala governorate Iraq." In THE 9TH INTERNATIONAL CONFERENCE ON APPLIED SCIENCE AND TECHNOLOGY (ICAST 2021). AIP Publishing, 2022. http://dx.doi.org/10.1063/5.0113631.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Vrancianu, Corneliu Ovidiu, Roxana-Elena Cristian, Elena-Georgiana Dobre, Catalina Zenoaga-Barbarosie, Ecaterina-Teodora Chirea, Ioana Crunteanu, and Mihai-Viorel Dionisie. "The Impact of Acinetobacter baumannii Infections in COVID-19 Patients Admitted in Hospital Intensive Care Units." In ECM 2023. Basel Switzerland: MDPI, 2023. http://dx.doi.org/10.3390/ecm2023-16479.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Grosse-Onnebrink, Joerg, Heymut Omran, Johanna Rudloff, and Claudius Werner. "Acinetobacter baumanii and Stenotrophomonas maltophilia are associated with lower airway infections in tracheostomised children and young adults." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa4137.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Hodyna, Diana. "LONG-CHAIN TRIPHENYLPHOSPHONIUM IONIC LIQUIDS AS ANTIBACTERIALS IN POTENTIAL POLYMICROBIAL INFECTIONS CAUSED BY STAPHYLOCOCCUS AUREUS AND ACINETOBACTER BAUMANNII STRAINS." In THEORETICAL AND PRACTICAL ASPECTS OF MODERN SCIENTIFIC RESEARCH, Chair Ivan Semenyuta, Sergiy Rogalsky, and Larysa Metelytsia. European Scientific Platform, 2023. http://dx.doi.org/10.36074/logos-28.04.2023.26.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Misri, A. R. "To Study the Epidemiology of Multidrug Resistant Acinetobacter Infections Among Critically Ill Adult Patients Admitted in Medical Intensive Care Unit." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a6508.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Infections à Acinetobacter – Chimiothérapie":

1

Meddaugh, Paul, and Uzo Chukwuma. Acinetobacter Species Infections Among Navy and Marine Corps Beneficiaries: 2013 Annual Report. Fort Belvoir, VA: Defense Technical Information Center, November 2014. http://dx.doi.org/10.21236/ada611595.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Meddaugh, Paul, and Uzo Chukwuma. Acinetobacter Species Infections among Navy and Marine Corps Beneficiaries: 2014 Annual Report. Fort Belvoir, VA: Defense Technical Information Center, July 2015. http://dx.doi.org/10.21236/ada621496.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Maraolo, Alberto Enrico, and David SY Ong. Colistin plus meropenem versus colistin alone for invasive infections caused by Carbapenem-Resistant Acinetobacter baumannii: a rapid systematic review of randomized controlled trials using Bayesian meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2023. http://dx.doi.org/10.37766/inplasy2023.1.0055.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Review question / Objective: What is the benefit stemming from meropenem add-on treatment to colistin against Carbapenem-Resistant strains of Acinetobacter baumannii? Condition being studied: Invasive infections caused by extensively drug-resistant (XDR) Acinetobacter baumannii, specifically carbapenem-resistant Acinetobacter baumannii (CRAB), are associated with high mortality above 50%, especially in critically ill patients. Often colistin is the only active agent in vitro and, although its safety issues, remains the cornerstone of therapy. Nevertheless, considering the relevant mortality rate when resorting to colistin alone, an intriguing idea is to exploit the potent in vitro synergy of colistin when combined with carbapenems.

До бібліографії